Key Highlights

  • Second-quarter Vyvgart net sales of $1.516 billion rose 60% year on year, and first-half net profit reached $838 million, with $5.2 billion of cash and current financial assets at 30 June 2026.
  • The 8.56% move on 23 July accounts for most of argenx's roughly 9% year-to-date gain, so the "momentum" narrative rests on one session rather than a sustained 2026 trend.
  • Two registrational readouts, ALKIVIA in myositis and EMPASSION in multifocal motor neuropathy, land before the end of 2026 and are genuine binary risks against a backdrop of intensifying FcRn competition.
  • Topline results from ALKIVIA in autoimmune myositis are expected in the third quarter of 2026, and EMPASSION, the registrational study of empasiprubart in multifocal motor neuropathy, in the fourth.

argenx (NASDAQ:ARGX) reported second-quarter Vyvgart net sales of $1.516 billion on 23 July, up 60% year on year and ahead of analyst consensus, and the Nasdaq-listed shares closed 8.6% higher the same day. The company is now durably profitable with $5.2 billion of liquidity, but the FcRn drug class it invented is becoming crowded and the 2026 share-price gain remains modest.

On Thursday 23 July 2026, argenx SE published half-year results that were, by the standards of commercial-stage biotechnology, unusually clean. Second-quarter net product sales of Vyvgart and Vyvgart Hytrulo reached $1.516 billion, up 60% on the same quarter of 2025 and 17% on the first three months of this year. Total operating income of $1.542 billion beat the consensus figure of roughly $1.45 billion compiled by MarketBeat, and diluted earnings of $7.32 per share came in above the $5.86 analysts had modelled. Nasdaq ADSs closed at $924.60, up 8.56% on the session. That one day accounts for most of what argenx shares have achieved in 2026.

What Happened

The quarter was the first full period to reflect a regulatory decision taken in May. On 8 May 2026, the US Food and Drug Administration approved a supplemental biologics licence application expanding the Vyvgart and Vyvgart Hytrulo labels to all adult patients with generalised myasthenia gravis, regardless of antibody serotype. Until then the drug had been restricted to patients testing positive for antibodies against the acetylcholine receptor. The expanded label now covers anti-MuSK-positive, anti-LRP4-positive and triple-seronegative patients, according to the company's approval announcement.

argenx told investors in its second-quarter presentation that the change opens access to roughly 11,000 additional US patients, that around 80% of physicians treating seronegative myasthenia gravis are now covered by its commercial infrastructure, and that about 55% of commercially insured lives had payer coverage for the expanded indication by the end of June. Vyvgart is also approved globally in chronic inflammatory demyelinating polyneuropathy and, in Japan, in primary immune thrombocytopenia.

Understanding the Science

Efgartigimod, sold as Vyvgart in its intravenous form and Vyvgart Hytrulo when co-formulated with hyaluronidase for subcutaneous delivery, is an engineered antibody fragment that blocks the neonatal Fc receptor, or FcRn.

FcRn acts as a recycling system for immunoglobulin G antibodies. Circulating IgG that would otherwise be broken down is captured by FcRn inside cells and returned intact to the bloodstream, which is why IgG persists for weeks rather than hours. In autoimmune diseases where the damaging agent is an IgG autoantibody, that recycling works against the patient. Efgartigimod occupies FcRn and prevents it from rescuing IgG, so total IgG levels fall and the pathogenic autoantibodies fall with them.

The approach is broadly applicable. Any disease driven principally by IgG autoantibodies is a plausible target, which is the basis for argenx's expansion into myositis, immune thrombocytopenia, Sjögren's disease, Graves' disease and ocular myasthenia gravis. The limitation is equally clear: diseases in which IgG is not the dominant driver are unlikely to respond, and the mechanism lowers protective antibodies alongside harmful ones.

The Clinical and Regulatory Evidence

The seronegative expansion rested on ADAPT SERON, a Phase 3 study in 119 patients with non-AChR-positive generalised myasthenia gravis run across North America, Europe, China and the Middle East. argenx reported a 3.35-point improvement in the MG-ADL symptom score at week four, with safety consistent with earlier trials. The FDA granted priority review with a target action date of 10 May 2026 and acted two days early.

A second Phase 3 readout arrived earlier in the year. On 26 February 2026 argenx announced topline results from ADAPT OCULUS in 141 adults with ocular myasthenia gravis, a milder form confined to the eye muscles. The trial met its primary endpoint, a change from baseline in the ocular score of the Myasthenia Gravis Impairment Index at week four, with a 4.04-point mean improvement against 1.99 points on placebo (p=0.012). A secondary measure of double vision and eyelid drooping was also positive (p=0.018). The company said no new safety signals emerged and that it intends to file with the FDA by the end of the third quarter of 2026. That filing has not been confirmed as submitted.

Data presented at the American Academy of Neurology meeting in April 2026 added supporting evidence in CIDP, including a post-hoc analysis in which 87.5% of treatment-naive patients showed early clinical improvement, with a median time to response of 39.5 days.

The Commercial Opportunity

Vyvgart's growth is still overwhelmingly American. Of the $1.516 billion booked in the quarter, the United States contributed $1.273 billion, up 59%, according to figures presented with the results. Japan grew fastest, rising 117% to $102 million, while the rest of the world added $136 million.

Two structural drivers sit behind the trajectory. The first is indication breadth: gMG, CIDP and Japanese ITP today, with the seronegative expansion widening the pool inside the largest existing indication rather than opening a new one. The second is convenience. The FDA approved a prefilled syringe for subcutaneous self-injection in April 2025, moving patients away from infusion centres, and argenx has said an autoinjector is positioned for launch in 2027.

Management frames this within a target it calls Vision 2030: treating 50,000 patients worldwide, holding ten labelled indications, and moving five further pipeline candidates into registrational development by the end of the decade. Those are company ambitions rather than guidance, and argenx does not publish quarterly patient counts against them.

Financial Position

The half-year accounts show a business that has crossed from cash consumption to cash generation. First-half product net sales of $2.813 billion compare with $1.739 billion a year earlier. Research and development rose to $929 million from $642 million and selling, general and administrative costs to $772 million from $601 million, so spending remains heavy, but revenue is outrunning both.

Operating profit for the half reached $887 million against $340 million, and net profit was $838 million versus $415 million, giving diluted earnings of $13.00 per share on about 64.4 million weighted average diluted shares. Operating cash flow swung to a positive $0.7 billion from an outflow of $0.4 billion a year earlier.

Liquidity stood at $5.2 billion on 30 June 2026, comprising $3.6 billion of cash and equivalents plus $1.6 billion of current financial assets, up from $4.4 billion at the end of 2025. With operations self-funding, runway is no longer the constraint it once was.

The Stock-Market Reaction

The move worth examining is the one-day reaction rather than any longer trend. ARGX closed at $846.19 on 20 July and $851.72 on 22 July, then jumped 8.56% to $924.60 on results day before easing 0.69% to $918.22 on 24 July.

Zoom out and the picture is less dramatic than a momentum narrative implies. argenx began 2026 at about $840.95, so the year-to-date gain as of 24 July was roughly 9%, achieved almost entirely in that single session. The twelve-month comparison is far stronger, with Investing.com reporting a 71.65% one-year gain in early July, but that reflects a re-rating that largely happened during 2025. The 52-week range runs from $577.04 to $953.58, and the shares trade near, though not at, the top of it. Market capitalisation is around $57 billion, a price that already embeds several years of continued expansion.

Key Growth Catalysts

argenx has set out a dense readout calendar. Topline results from ALKIVIA in autoimmune myositis are expected in the third quarter of 2026, and EMPASSION, the registrational study of empasiprubart in multifocal motor neuropathy, in the fourth. Empasiprubart is an anti-C2 antibody targeting the complement cascade rather than FcRn, and is argenx's most advanced attempt to prove it is more than a one-mechanism company.

Further out, the company expects ADVANCE-NEXT in primary immune thrombocytopenia in the first half of 2027, and UNITY in Sjögren's disease plus the EMVIGORATE and EMNERGIZE studies of empasiprubart in CIDP in the second half. A registrational study in Graves' disease is running. Next-generation FcRn candidates ARGX-213, described as Phase 3 ready with monthly dosing, and ARGX-124 are meant to defend the franchise.

Major Risks

The most immediate risk is competitive. argenx created the FcRn category but no longer owns it. Johnson & Johnson's nipocalimab, marketed as Imaavy, was approved in the United States in 2025 with a label reaching patients from age 12. UCB sells rozanolixizumab under the Rystiggo brand and the complement inhibitor zilucoplan as Zilbrysq. Amgen has reported positive Phase 3 results for inebilizumab in gMG, and cell-therapy programmes including Cartesian Therapeutics' Descartes-08 and Kyverna's KYV-101 are pursuing a mechanistically different route that could in principle deliver longer-lasting remission. Head-to-head data across these agents remains scarce, so claims of superiority in either direction are not currently supportable.

Concentration is the second risk. Essentially all of argenx's revenue comes from one molecule, and roughly 84% from one country. Any change to US reimbursement, pricing or payer behaviour would land directly on the income statement.

Third, the pipeline that justifies the valuation is unproven. A positive Phase 3 in ocular myasthenia gravis does not guarantee approval, and a mechanism that works in one antibody-driven disease has repeatedly failed to translate in others. The ALKIVIA and EMPASSION readouts due within six months are genuine binary events. Lowering IgG also carries an inherent infection risk requiring long-term monitoring as the treated population widens. Leadership changed recently too: Karen Massey became chief executive on 6 May 2026, with founder Tim Van Hauwermeiren moving to non-executive board chair.

Conclusion

The verified facts describe a company executing well. Sixty per cent sales growth at a $6 billion annualised run rate, genuine profitability, positive operating cash flow and $5.2 billion on the balance sheet are not contested. Whether that converts into durable leadership in immunology depends on readouts that have not happened yet.

argenx has proven that efgartigimod works in myasthenia gravis and CIDP and that it can sell it. It has not proven that the same mechanism, or empasiprubart, extends across the further indications implied by its 2030 ambitions, or that it can hold share as better-funded rivals arrive. With the shares near record levels but up only about 9% this year, the market appears to be waiting for those answers rather than assuming them.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.